Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | Ruxolitinib plus azacitidine for myelofibrosis

Naval Daver • 18 Dec 2018
ASH 2018
Myelofibrosis Myeloproliferative Neoplasms Azacitidine Ruxolitinib

Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, presents the results of a Phase II study of ruxolitinib in combination with azacitidine in patients with myelofibrosis (NCT01787487), which were reported at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Naval Daver

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
Approaches to managing FLT3-mutant AML 12:59
Approaches to managing FLT3-mutant AML
Alexander Perl et al. • 20 Sep 2025
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025 11:48
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025
Naval Daver • 21 Sep 2025

Related Videos

Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera 2:04
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar • 8 Dec 2025
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET 2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms 1:39
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
Roman Doll • 7 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals